Option Care Health (NASDAQ:OPCH) Sets New 12-Month High – Time to Buy?

Shares of Option Care Health, Inc. (NASDAQ:OPCH) reached a new 52-week high during trading on Monday . The stock traded as high as $35.46 and last traded at $34.97, with a volume of 529 shares trading hands. The stock had previously closed at $34.58.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. UBS Group assumed coverage on shares of Option Care Health in a report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 target price for the company. JPMorgan Chase & Co. raised their target price on shares of Option Care Health from $40.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, March 6th. Bank of America upgraded shares of Option Care Health from a “neutral” rating to a “buy” rating and raised their target price for the stock from $26.00 to $33.00 in a report on Monday, January 13th. Barrington Research raised their target price on shares of Option Care Health from $33.00 to $38.00 and gave the stock an “outperform” rating in a report on Thursday, February 27th. Finally, Jefferies Financial Group upgraded shares of Option Care Health from a “hold” rating to a “buy” rating and lifted their price objective for the company from $26.00 to $35.00 in a report on Thursday, January 23rd. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Option Care Health presently has an average rating of “Moderate Buy” and a consensus price target of $33.00.

Option Care Health Stock Performance

The company has a market cap of $5.78 billion, a PE ratio of 29.47, a P/E/G ratio of 2.30 and a beta of 1.33. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. The firm’s 50-day simple moving average is $31.84 and its two-hundred day simple moving average is $28.29.

Insiders Place Their Bets

In other Option Care Health news, insider Michael Bavaro sold 30,996 shares of Option Care Health stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the completion of the sale, the insider now directly owns 44,974 shares in the company, valued at approximately $1,495,835.24. The trade was a 40.80 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.64% of the stock is owned by insiders.

Institutional Trading of Option Care Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Murphy & Mullick Capital Management Corp acquired a new position in shares of Option Care Health in the 4th quarter valued at $26,000. UMB Bank n.a. lifted its stake in shares of Option Care Health by 41.7% in the 4th quarter. UMB Bank n.a. now owns 1,176 shares of the company’s stock valued at $27,000 after purchasing an additional 346 shares during the period. Signaturefd LLC lifted its stake in shares of Option Care Health by 487.9% in the 4th quarter. Signaturefd LLC now owns 1,211 shares of the company’s stock valued at $28,000 after purchasing an additional 1,005 shares during the period. Quadrant Capital Group LLC lifted its stake in shares of Option Care Health by 172.8% in the 4th quarter. Quadrant Capital Group LLC now owns 1,735 shares of the company’s stock valued at $40,000 after purchasing an additional 1,099 shares during the period. Finally, Public Employees Retirement System of Ohio lifted its stake in shares of Option Care Health by 21.6% in the 4th quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company’s stock valued at $43,000 after purchasing an additional 332 shares during the period. 98.05% of the stock is currently owned by institutional investors and hedge funds.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.